ALK and neoplasm: All five analyzed samples of the patient showed the EML4–ALK V2 fusion, while there was no evidence of any other fusion or single-nucleotide variant (SNV) in the regions covered by our 38–42-gene panel (Table 1); in particular, TP53wt and RB1wt were confirmed by analysis of the second tumor rebiopsy using the TruSight Oncology 500 (TSO500) panel, which covers all TP53 and RB1 exons, including splice sites, as well as sensitive detection of copy-number variations, and showed no mutation or deletion of these two genes (Table 1).